Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
暂无分享,去创建一个
J. Leonard | J. Radford | Hao Tang | S. Rodig | D. Cunningham | P. Armand | S. Ansell | Peter W. M. Johnson | J. Timmerman | G. Gritti | A. Janssens | A. Sumbul | A. Pinto | P. Martín-Regueira | S. Mercadal Vilchez | S. Samakoglu | P. Johnson
[1] W. Klapper,et al. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Gribben,et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Klein,et al. Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma , 2019, Oncoimmunology.
[4] K. Savage,et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Radford,et al. Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma , 2018, JAAD case reports.
[6] Sonali M. Smith,et al. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] R. Davis,et al. High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study , 2017 .
[8] J. Myklebust,et al. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling , 2017, Clinical Cancer Research.
[9] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[10] G. Lenz,et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Salles,et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. , 2017, Blood.
[12] Y. Oki,et al. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study. , 2017 .
[13] Hyo Jin Kim,et al. Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma , 2017, Oncotarget.
[14] Indicators of responsiveness to immune checkpoint inhibitors , 2017, Scientific Reports.
[15] M. Millenson,et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Robert Kridel,et al. Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement , 2016, Oncoimmunology.
[17] A. Nademanee,et al. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] M. Czuczman,et al. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Brousset,et al. Several immune escape patterns in non-Hodgkin's lymphomas , 2015, Oncoimmunology.
[20] J. Cerhan,et al. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. , 2015, Blood.
[21] S. Ansell,et al. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival , 2015, Blood Cancer Journal.
[22] R. Davis,et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. , 2014, The Lancet. Oncology.
[23] M. Seto,et al. Clinical Significance of sIL-2R Levels in B-Cell Lymphomas , 2013, PloS one.
[24] Ash A. Alizadeh,et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. , 2013, Blood.
[25] S. Ansell,et al. Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. , 2011, Blood.
[26] G. Pinkus,et al. Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells , 2011, Clinical Cancer Research.
[27] T. Habermann,et al. Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma , 2009, Clinical Cancer Research.
[28] J. Radford,et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. , 2008, Blood.
[29] J. Gribben. How I treat indolent lymphoma. , 2007, Blood.
[30] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] L. Staudt,et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.